U.S. markets open in 2 hours 13 minutes
  • S&P Futures

    3,429.00
    -3.25 (-0.09%)
     
  • Dow Futures

    28,138.00
    -44.00 (-0.16%)
     
  • Nasdaq Futures

    11,647.25
    -13.50 (-0.12%)
     
  • Russell 2000 Futures

    1,612.40
    -2.40 (-0.15%)
     
  • Crude Oil

    40.96
    -0.74 (-1.77%)
     
  • Gold

    1,921.50
    +6.10 (+0.32%)
     
  • Silver

    25.13
    +0.15 (+0.60%)
     
  • EUR/USD

    1.1864
    +0.0035 (+0.30%)
     
  • 10-Yr Bond

    0.7970
    0.0000 (0.00%)
     
  • Vix

    29.95
    +0.77 (+2.64%)
     
  • GBP/USD

    1.3057
    +0.0110 (+0.85%)
     
  • USD/JPY

    104.8460
    -0.6240 (-0.59%)
     
  • BTC-USD

    12,219.41
    +1,162.40 (+10.51%)
     
  • CMC Crypto 200

    245.48
    +6.56 (+2.75%)
     
  • FTSE 100

    5,815.26
    -73.96 (-1.26%)
     
  • Nikkei 225

    23,639.46
    +72.42 (+0.31%)
     

Do Institutions Own Australian Pharmaceutical Industries Limited (ASX:API) Shares?

Simply Wall St
·5 mins read

If you want to know who really controls Australian Pharmaceutical Industries Limited (ASX:API), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Companies that used to be publicly owned tend to have lower insider ownership.

Australian Pharmaceutical Industries is not a large company by global standards. It has a market capitalization of AU$503m, which means it wouldn't have the attention of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about Australian Pharmaceutical Industries.

View our latest analysis for Australian Pharmaceutical Industries

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Australian Pharmaceutical Industries?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that Australian Pharmaceutical Industries does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Australian Pharmaceutical Industries, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in Australian Pharmaceutical Industries. Washington H. Soul Pattinson and Company Limited is currently the largest shareholder, with 19% of shares outstanding. With 5.1% and 4.9% of the shares outstanding respectively, First Sentier Investors (Australia) IM Ltd and LSV Asset Management are the second and third largest shareholders.

Our studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

Insider Ownership Of Australian Pharmaceutical Industries

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own some shares in Australian Pharmaceutical Industries Limited. In their own names, insiders own AU$8.0m worth of stock in the AU$503m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.

General Public Ownership

The general public, mostly retail investors, hold a substantial 54% stake in Australian Pharmaceutical Industries, suggesting it is a fairly popular stock. This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and the dividend payout ratio.

Public Company Ownership

It appears to us that public companies own 19% of Australian Pharmaceutical Industries. This may be a strategic interest and the two companies may have related business interests. It could be that they have de-merged. This holding is probably worth investigating further.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Australian Pharmaceutical Industries better, we need to consider many other factors.

I always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.